Compare Adaptive Biotechnologies Corp (ADPT) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Vanguard Information Technology Index Fund ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.87 (market cap $3.33B), while Vanguard Information Technology Index Fund ETF trades at $114.63. Which is the better fit depends on your goals.
| ADPT | VGT | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $125.77 |
52-Week Low | $10.24 | $83.59 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
The Vanguard Information Technology ETF (VGT) trades at $116.37, up 1.51% on the day, with technical indicators showing a mixed but slightly bullish bias. The fund recently executed an 8-for-1 stock split and maintains a low 0.09% expense ratio, positioning it as a cost-efficient vehicle for broad tech exposure. Financial media sentiment is generally positive, highlighting VGT's strong long-term track record and diversification benefits compared to more concentrated tech ETFs.
The outlook for VGT is tied to the broader technology sector's performance, particularly hyperscaler capital expenditure and semiconductor cycles. Key opportunities include exposure to AI-driven growth through a diversified portfolio. Primary risks involve sector concentration, market volatility, and potential valuation pressures if tech earnings growth decelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
